RA’ANANA, Israel & NEW YORK--(BUSINESS WIRE)--Sep. 25, 2018--
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical
company developing treatments to address unmet needs in the field of
urology, with a focus on uro-oncology, today announced that Ron Bentsur,
Chief Executive Officer, will present at the Ladenburg Thalmann 2018
Healthcare Conference in New York, NY on Tuesday, October 2, 2018 at
2:30PM Eastern Time.
A live audio webcast of the event will be available on the Investors
section of UroGen's website, www.urogen.com.
A replay of the webcast will be available on the website for
approximately two weeks following the live presentation.
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical
company developing advanced non-surgical treatments to address unmet
needs in the field of urology, with a focus on uro-oncology. UroGen has
developed RTGel™, a proprietary sustained release, hydrogel-based
platform technology that has the potential to improve therapeutic
profiles of existing drugs. UroGen’s sustained release technology is
designed to enable longer exposure of the urinary tract tissue to
medications, making local therapy a potentially more effective treatment
option. UroGen’s lead product candidates, UGN-101 (mitomycin gel for
urothelial instillation), formerly known as MitoGel®, and UGN-102
(mitomycin gel for intravesical instillation), formerly known as
VesiGel™, are designed to potentially remove tumors by non-surgical
means and to treat several forms of non-muscle invasive urothelial
cancer, including low-grade upper tract urothelial carcinoma and bladder
cancer, respectively. UroGen is headquartered in Ra’anana, Israel with
U.S. headquarters in New York.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180925005126/en/
Source: UroGen Pharma Ltd.
Director, Corporate Communications
& Investor Relations